La Jolla Pharmaceutical Company (LJPC)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
La Jolla Pharmaceutical Company (LJPC) trades at $6.19 with AI Score 63/100 (Hold). La Jolla Pharmaceutical Company, a subsidiary of Innoviva, Inc. , focuses on developing and commercializing therapies for life-threatening diseases. Market cap: $0, Sector: Healthcare.
Last analyzed: Feb 8, 2026La Jolla Pharmaceutical Company (LJPC) Healthcare & Pipeline Overview
La Jolla Pharmaceutical Company (LJPC) offers targeted therapies for critical care, including GIAPREZA and XERAVA, addressing unmet needs in life-threatening conditions. With a strong gross margin of 82.2% and a P/E ratio of 10.76, LJPC presents a notable research candidate within the biotechnology sector.
Investment Thesis
La Jolla Pharmaceutical Company presents a notable research candidate due to its focus on critical care therapies and established products like GIAPREZA and XERAVA. The company's high gross margin of 82.2% indicates strong pricing power and efficient operations. With a P/E ratio of 10.76, LJPC appears undervalued compared to its peers, suggesting potential for capital appreciation. Growth catalysts include the expansion of GIAPREZA and XERAVA into new markets through existing licensing agreements with Everest Medicines Limited and PAION AG. Furthermore, the development of their pipeline candidates, such as TP-6076, TP-271, and TP-2846, offers long-term growth potential. The company's strategic focus on addressing unmet needs in life-threatening diseases positions it favorably within the biotechnology sector. Investors may want to evaluate LJPC for its potential to deliver both near-term profitability and long-term value creation.
Based on FMP financials and quantitative analysis
Key Highlights
- GIAPREZA is a key product indicated to increase blood pressure in adults with septic or other distributive shock.
- XERAVA, a tetracycline class antibacterial, is used for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.
- Gross Margin of 82.2% demonstrates efficient operations and strong pricing power.
- P/E ratio of 10.76 suggests potential undervaluation compared to industry peers.
- La Jolla Pharmaceutical Company operates as a subsidiary of Innoviva, Inc., providing potential synergies and stability.
Competitors & Peers
Strengths
- Established products: GIAPREZA and XERAVA.
- High gross margin of 82.2%.
- Strategic partnerships with Everest Medicines Limited and PAION AG.
- Focus on addressing unmet needs in life-threatening diseases.
Weaknesses
- Reliance on a limited number of products.
- Early-stage pipeline with associated development risks.
- Dependence on partners for commercialization in certain territories.
- Subsidiary status may limit strategic autonomy.
Catalysts
- Upcoming: Clinical trial results for TP-6076, TP-271, and TP-2846.
- Ongoing: Expansion of GIAPREZA and XERAVA sales through existing partnerships.
- Ongoing: Potential for new licensing agreements or acquisitions.
Risks
- Potential: Clinical trial failures for pipeline candidates.
- Potential: Regulatory delays or rejection of new drug applications.
- Ongoing: Competition from other pharmaceutical companies.
- Ongoing: Dependence on partners for commercialization success.
- Potential: Changes in reimbursement policies or pricing pressures.
Growth Opportunities
- Expansion of GIAPREZA into New Markets: La Jolla Pharmaceutical Company has the opportunity to expand the market reach of GIAPREZA through its licensing agreement with PAION AG. This collaboration allows for commercialization in territories outside the United States, potentially increasing revenue streams and market share. The global market for vasopressors is estimated to reach $1.5 billion by 2028, providing a significant growth runway for GIAPREZA.
- Commercialization of XERAVA through Partnerships: The license agreement with Everest Medicines Limited to develop and commercialize XERAVA presents a significant growth opportunity in Asia. The rising prevalence of antibiotic-resistant infections in the region creates a strong demand for effective antibacterial treatments like XERAVA. This partnership can drive substantial revenue growth and establish a strong presence in the Asian market.
- Development of TP-6076 for Multidrug-Resistant Infections: The development of TP-6076, an IV formulation targeting multidrug-resistant gram-negative bacteria, addresses a critical unmet need in the treatment of severe infections. With increasing rates of antibiotic resistance, the market for novel antibacterial agents is expanding rapidly. Successful clinical development and commercialization of TP-6076 could generate significant revenue and establish La Jolla Pharmaceutical Company as a leader in the field.
- Advancement of TP-271 for Respiratory Diseases: TP-271, an IV and oral formulation for respiratory diseases caused by bacterial biothreats, represents a strategic opportunity to address public health concerns and potential biodefense needs. Government funding and initiatives focused on biodefense create a favorable environment for the development and commercialization of TP-271. This program could provide a stable revenue stream and contribute to national security.
- Exploration of TP-2846 for Acute Myeloid Leukemia: The development of TP-2846, an IV formulation for the treatment of acute myeloid leukemia, diversifies La Jolla Pharmaceutical Company's pipeline into oncology. The market for AML therapies is growing due to advancements in diagnostics and treatment options. Successful development and commercialization of TP-2846 could expand the company's revenue base and establish a presence in the oncology market.
Opportunities
- Expansion of GIAPREZA and XERAVA into new markets.
- Successful development and commercialization of pipeline candidates.
- Acquisition or in-licensing of complementary products or technologies.
- Increased government funding for biodefense and antibiotic resistance initiatives.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles and clinical trial failures.
- Pricing pressures and reimbursement challenges.
- Patent expirations and generic competition.
Competitive Advantages
- Proprietary drug formulations with patent protection.
- Established relationships with hospitals and healthcare organizations.
- Strategic partnerships for global commercialization.
- Specialized expertise in developing therapies for life-threatening diseases.
About LJPC
La Jolla Pharmaceutical Company, incorporated in 1989, is dedicated to the development and commercialization of innovative therapies aimed at improving patient outcomes in life-threatening diseases. The company's core focus lies in addressing critical unmet needs within the healthcare sector, particularly in the treatment of severe conditions such as septic shock and complicated intra-abdominal infections. Their primary products include GIAPREZA, a vasoconstrictor approved to increase blood pressure in adults experiencing septic or other distributive shock, and XERAVA, a tetracycline-class antibacterial designed for treating complicated intra-abdominal infections in patients aged 18 and older. These products are primarily offered to hospitals and healthcare organizations throughout the United States. In addition to their marketed products, La Jolla Pharmaceutical Company has a pipeline of early-stage clinical and preclinical product candidates, including TP-6076, an IV formulation targeting multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation for respiratory diseases caused by bacterial biothreats; and TP-2846, an IV formulation for the treatment of acute myeloid leukemia. As of August 22, 2022, La Jolla Pharmaceutical Company operates as a subsidiary of Innoviva, Inc., marking a significant evolution in its corporate structure and strategic direction. The company also has license agreements with Everest Medicines Limited to develop and commercialize XERAVA and PAION AG to commercialize GIAPREZA and XERAVA.
What They Do
- Develop and commercialize therapies for life-threatening diseases.
- Offer GIAPREZA, a vasoconstrictor for septic shock.
- Offer XERAVA, an antibacterial for complicated intra-abdominal infections.
- Develop TP-6076 for multidrug-resistant gram-negative bacteria.
- Develop TP-271 for respiratory diseases caused by bacterial biothreats.
- Develop TP-2846 for acute myeloid leukemia.
- License products to partners like Everest Medicines Limited and PAION AG.
Business Model
- Develop and obtain regulatory approval for pharmaceutical products.
- Manufacture and market GIAPREZA and XERAVA directly to hospitals and healthcare organizations in the United States.
- Generate revenue through product sales.
- License products to partners for commercialization in other territories, receiving royalties and milestone payments.
Industry Context
La Jolla Pharmaceutical Company operates within the biotechnology industry, which is characterized by rapid innovation, high regulatory hurdles, and significant growth potential. The market for critical care therapies, particularly those addressing septic shock and severe infections, is substantial and growing due to increasing rates of antibiotic resistance and aging populations. The competitive landscape includes companies like ATYR, EXOZ, FSTX, LENZ, and NGM, each with its own focus and therapeutic pipeline. La Jolla Pharmaceutical Company differentiates itself through its established products, GIAPREZA and XERAVA, and its strategic focus on addressing unmet needs in life-threatening diseases.
Key Customers
- Hospitals and healthcare organizations in the United States.
- Patients suffering from septic shock.
- Patients with complicated intra-abdominal infections.
- Partners like Everest Medicines Limited and PAION AG.
Financials
Chart & Info
La Jolla Pharmaceutical Company (LJPC) stock price: $6.19 (+0.00, +0.00%)
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Jun 14, 2022
-
Stocks That Hit 52-Week Lows On Monday
· Nov 25, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LJPC.
Price Targets
Wall Street price target analysis for LJPC.
MoonshotScore
What does this score mean?
The MoonshotScore rates LJPC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
La Jolla Pharmaceutical Company Stock: Key Questions Answered
What does La Jolla Pharmaceutical Company do?
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on developing and commercializing therapies for life-threatening diseases. Its key products include GIAPREZA, a vasoconstrictor used to increase blood pressure in adults with septic shock, and XERAVA, an antibacterial for treating complicated intra-abdominal infections. The company generates revenue through direct sales of these products to hospitals and healthcare organizations in the United States and through licensing agreements with partners for commercialization in other territories. La Jolla Pharmaceutical Company also has a pipeline of early-stage product candidates targeting multidrug-resistant infections and other critical medical needs.
Is LJPC stock worth researching?
LJPC's stock presents a mixed investment profile. The company's high gross margin of 82.2% and a P/E ratio of 10.76 suggest potential undervaluation. Growth opportunities include expanding the market reach of GIAPREZA and XERAVA through partnerships and advancing its pipeline candidates. However, risks include reliance on a limited number of products, regulatory hurdles, and competition. Investors should carefully consider these factors and conduct thorough due diligence before investing in LJPC stock.
What are the main risks for LJPC?
La Jolla Pharmaceutical Company faces several key risks. Clinical trial failures for its pipeline candidates could significantly impact future growth prospects. Regulatory delays or rejection of new drug applications could also hinder commercialization efforts. The company faces competition from established pharmaceutical companies and is dependent on partners for commercialization success in certain territories. Changes in reimbursement policies or pricing pressures could negatively affect revenue and profitability. These risks should be carefully considered by potential investors.
What are the key factors to evaluate for LJPC?
La Jolla Pharmaceutical Company (LJPC) currently holds an AI score of 63/100, indicating moderate score. Key strength: Established products: GIAPREZA and XERAVA.. Primary risk to monitor: Potential: Clinical trial failures for pipeline candidates.. This is not financial advice.
How frequently does LJPC data refresh on this page?
LJPC prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven LJPC's recent stock price performance?
Recent price movement in La Jolla Pharmaceutical Company (LJPC) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established products: GIAPREZA and XERAVA.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider LJPC overvalued or undervalued right now?
Determining whether La Jolla Pharmaceutical Company (LJPC) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying LJPC?
Before investing in La Jolla Pharmaceutical Company (LJPC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Stock data pending update.